FierceBiotechOriginal article
{"a":[{"_":"Tyra rolls toward pivotal bladder cancer study even as midphase data deflates stock ","$":{"href":"/biotech/tyra-rolls-toward-pivotal-bladder-cancer-study-even-midphase-data-deflates-stock","hreflang":"en"}}]}
Phase 2MixeddabogratinibNegative
AI Analysis
Summary
Tyra Biosciences reported Phase 2 data on dabogratinib for bladder cancer with complete response rates below analyst expectations, though the company plans to advance to a registrational study next year. The disappointing efficacy results triggered premarket stock decline despite continued development momentum.
Clinical Trial Data
Phase
2
Primary Endpoint
Not Met
Outcome Details
Complete response rate fell short of analyst expectations
Importance:6/10
Sentiment:
-0.40
Phase 2 databladder cancerpivotal studymissed expectationsstock decline
Related Companies
Read the original article
Published by FierceBiotech on September 9, 2026 9:15 AM